Evidence accumulates suggesting that the pathogenesis in systemic lupus erythemato'iUs (SLE) is associated with modulations in the FaslFasL system. Serum concentrations of soluble Fas ligand (f;FasL) were found to be elevated in patients with SLE. In this study we wanted to determine the levels of sFasL and the status of immune activation -monitored by neopterin secretion -in patients with SLE and cutaneous discoid lupus erythematosus (C OLE). Sixty-five serum samples were assayed . We found elevated concentrations of sFasL in patients with SLE and COLE. The levels of sFasL in COLE patients were significant lower compared to SLE patients. '\eopterin concentrations in serum were found to be slightly increased in patients with CDLE. Compared to pati ents with SLE, activation of the immune system was significant lower in COLE. Taken together, we found d evated levels of sFasL in patients with SLE as well as COLE, connected with ar acti vation of the immune .;ystem and thereby increased concentration ofneopterin in serum .
Introduction
SLE is characterized by impaired T cell regulation :md B cell hyperactivity, leading to autoantibody production and subsequent tissue damage by immune complexes [I}. Accumulating evidence suggests that Fas-mediated apoptosis plays an important role in the immune system, e. g. , elimination of immature selfreactive T cells by elonal deletion in the thymus, T cell-mediated cytotoxicity, and activation-induced T cell apoptosis [reviewed in 2] . Mouse models with mutations in the Fas gene (lpr-mutation) or in the FasL gene (gld-mutation) [3] [4] [5] , and mice transgenic for overexpression of bcl-2 [6] [7] [8] develop clinical features similar to those of human SLE. This suggests that the FaslFasL-pathway and bcl-2 -both crucially involved in the regulation of apoptotic cell deathmay be implied in the pathogenesis of SLE. In a portion of SLE patients T cells overexpressing the bel-2 protein were detected [9] . Further, modulation of the FaslFasL system by enhanced secretion of sFas was observed in patients with SLE [10. 11, 12] . Increased expression of FasL in isolated lymphoC)1es from SLE patients and the presellce of circulating anti-FasL autoantibody was report ~d [11 , 13, 14] .
N eopterin (6-D-erytlu o-trih ydroxypropy Ipterin) and 7,8-dihydroneopterin 2fe small molecules (253 and 255 D), which are produced and secreted by human monocytes/macropha ges upon stimulation with interferon-y (IFN-y) [15] in a nearly constant ratio of 1 :3 [16] . Increased neopterin levels in patients indicate endoger.olls IFN-y production and macrophage activation [17] . Elevated concentrations of neopterin are found in various diseases associated with activation of cell-mediated immunity, e. g., viral infections including HIV -1 infection, allograft rejection, malignant tumors and autoimmune diseases [17] [18] [19] [20] [21] [22] . Urine and serum neopterin concentrations were found to closely correlate with disease activity in SLE [21, 22] . Reactive oxygen species (ROS) are known to be involved in the pathogenesis of SLE, particularly in processes leading to the formation of pathological anti-DNA antibodies [23, 24] . Recent studies imply a possible role of neopterin-derivatives in oxygen radical-mediated pro-cesses including activation of redox-sensitive transcription factors NF- [27] .
In this study we wanted to investigate the production of sFasL and neopterin in patiellts with SLE and with a cutaneous form of lupus erythematosus (CDLE). A possible relation between expr ,ssion of sFasL and production of neopterin-derivanves as markers for activated cell-mediated immunity .md compounds able to interfere with redox-regulated processes was tested.
Patients and Methods

Patients
Serum samples were obtained from patients with SLE (n = 49; 40 female and 9 male, ages 20-77 years) or CDLE (n = 16; 11 female and 5 male, ages 25-65 years). Most SLE patients received intermed,ate doses of corticosteroids (prednisone). Clinical features pf the patients are presented in Table 1 . Disease activity was classified using the SLEDAI score [28). A ll S LE patients fulfilled the ARA criteria [29] .
Measurement ofsFasL and neopterin levels
Concentrations of sFasL and neopterin III serum samples were detected by ELISA assays (sFasL ELISA Kit, Medical & Biological Laboratories Co. , Naka-ku Nagoya, Japan; Neopterin ELISA, Brahms Diagnostica, Berlin, Germany) . Optical density (OD) was measured on an Anthos Labtec ELISA Reader (Anthos Labtec, Salzburg, Austria) .
Detection of autoantibodies
The presence of antinuclear antibodies (ANA) was determined by immunofluorescence on HEp-2 cells . Antibodies directed against native DNA were tested using Crithidium lucillae as an antigen substrate. AntiRo/SS-A, anti-La/SS-B, anti-snRNP, anti-SM, anticardiolipin IgG and IgM were assayed using commercial ELISA-Kits.
Statistical analysis
Data showed no normal distribution. Therefore, the non-parametric Mann-Whitney U test was chosen to calculate differences between groups, correlation was estimated using the Spearman's rank correlation coefficient (rs).
Results
Sensitivity limit of the sFasL ELISA used in this study was 0.10 ng/rnl sFasL in serum (39 out of 40 healthy persons tested from the manufacturer had sFasL levels less than 0.100 nglml, one serum showed a value of 0.11 ng/ml). Due to this detection limit no patients (2 %) showed sFasL concentrations below the detection limit (0.10 ng/m1). Mean level of sFasL in sera ofCDLE patients was 0.16 ± 0.11 ng/ml (mean ± standard division) compared to 0.25 ± 0.10 ng/ml in SLE patients (Fig. 1) . The difference of sFasL concentrations between the two groups of patients tested was significant (P < 0.05). Mean serum neopterin level in patients with CD I~E was 6.4 ± 1.9 nrnoVI compared to 13 .2 ± 10.7 nmoL'1
In SLE patients (Fig.2) . Among the 65 persons assayed in this study 28 SLE (57.1%) showed serum neopterin concentrations higher than the 95 th percentile in healthy subjects (= 8.7 nrnoVI) . In contrast, in only 2 CDLE patients (12.5 %) elevated neopterin levels were detected in this study. According to the Mann-Whitney U test significant differences in neopterin levels (P < 0.001) between patients with SLE and CDLE were calculated. The correlation between sFasL levels and neopterin concentrations in patients with SLE and CDLE was assayed. A slight correlation between sFasL levels and ,erum neopterin was observed in SLE patients '.IS = 0.283, P < 0.05), but not in CDLE patients. \'alues are shown in Fig. 3 .
Discussion
Evidence accumulates suggesting that the pathogenesis in SLE is associated with modulations in the Fas/FasL system [2-5 , [10] [11] [12] [13] . In connection with these findings , apoptosis was found to be accelerated in lymphocytes isolated from SLE patients [30] . The data presented here confirm reports in which expression of sFasL was found to be elevated in serum of patients with SLE and in skin lesions of patients with cutaneous lupus [11, 31] . In our study sFasL concentration were found to be elevated in serum of patients with SLE and CDLE. In SLE patients sFasL levels were significantly lower compared to CDLE patients. This finding fit very well to studies suggesting an impact of increased expression of Fas and FasL in organ-specific damage in autoimmune disease [32, 12] .
During chronic inflammation in SLE increased infiltration of phagocytic cells leads to enhanced formation of ROS [33] . Chronic autoimmune inflammation in SLE is also associated with enhanced endogenous release of cytokines e. g. interleukin-(IL)-1, IL-2, IL-6 and IFN-y [reviewed in 34]. IFN-y stimulates the formation and secretion of neopterin and 7,8-dihydroneopterin in human monocytes/macrophages [15] . Neopterin levels were found to be elevated in patients with SLE, correlating with disease activity [21, 22] . This findings fit very well to our observations showing enhanced neopterin secretion ill SLE patients. Increased neopterin 87 concentrations were detected in a small proportion of patients with CDLE in this study.
In vitro studies revealed that the reduced form of neopterin, 7, 8-dihydroneopterin can induce apoptosis in Jurkat T lymphocytes [35] Most recently, increased expression of the FasL in Jurkat T lymphocytes by 7,8-dihydroneopterin was detected [27] . Interestingly, IFN-y, which stimulates the production and secretion of neopterin and 7,8-dihydroneopterin was shown to playa major role in the up-regulation of FaslFasL in acute graft-versushost disease [36] . In this context, a correlation between neopterin secretion and sFasL production should be calculated. A slight correlation between sFasL levels and serum neopterin was observed in SLE patients, but not in CDLE patients. . Taken together, we found that sFasL concentratIOns arc elevated in patients with SLE and the local cutaneous form of lupus erythematosus. Compared to sFasL levels in SLE, concentrations were significantly lower in patients with CDLE. In correlation with these findings , neopterin secretion and thereby immune activation was found to be slightly accelerated III patients with CDLE. In sera of patients with SLE, neopterin levels were significantly higher compared to patients with CDLE. Further, a slight correlation between serum levels of sFasL and neopterin secretion in SLE patients was calculated, but not in CDLE. Our results could indicate a possible role of the FaslFasL system combined with immune activation not only in SLE but also in CDLE.
